Company news
CelLBxHealth plc news in 2020
CelLBxHealth plc's news releases, calls and decks from 2020, newest first.
Parsortix can capture single cancer cell in sample
December 9, 2020
Result of General Meeting
November 13, 2020
Result of Placing & Notice of General Meeting
October 27, 2020
Submission accepted by FDA for substantive review
October 20, 2020
ANGLE announces completion of FDA submission
September 28, 2020
Potential treatment strategy to limit metastasis
September 23, 2020
Notification of Interim Results and Webcast
September 2, 2020
Result of 2020 Annual General Meeting
August 27, 2020
Parsortix use to assess response to immunotherapy
August 14, 2020
Notice of AGM and Posting of Annual Report
August 5, 2020
Study: Parsortix use in metastatic breast cancer
July 20, 2020
Blood donations recommenced for FDA studies
June 22, 2020
CTC potential as biomarker in MET inhibitor trials
May 12, 2020
Leading cancer centre publishes Parsortix workflow
May 4, 2020
Business Update
April 28, 2020
Parsortix performance in head and neck cancer
April 17, 2020
COVID-19 business impact update
March 31, 2020
Assessing risk of brain metastasis in lung cancer
March 3, 2020
Parsortix outperforms other CTC systems in RCC
February 27, 2020
ANGLE announce Tri-Con presentation with BioView
February 25, 2020
Data demonstrates key advantages of Parsortix
February 17, 2020
Study demonstrates Parsortix potential in melanoma
February 11, 2020
Change of accounting reference date
January 30, 2020
Successful face-to-face meeting with FDA
January 22, 2020